The Use of Natural Products for Preventing Cognitive Decline/Providing Neuroprotection
Handbook of Experimental Pharmacology · 2025
DOI: 10.1007/164_2024_732 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Handbook of Experimental Pharmacology, 2025. Verfasst von Ozra Tabatabaei-Malazy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran,…. Hauptthemen laut MEDLINE: Neuroprotective Agents, Cognitive Dysfunction, Biological Products, Cognition. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 112 Literaturangaben.
Abstract (Originalsprache)
Neurocognitive disorders are characterized by a decline in various components of cognitive function, resulting in a high rate of morbidity and mortality. Despite multiple efforts, there is still a lack of practical preventive and therapeutic approaches for these diseases, and current pharmaceuticals have failed to manage their progression. Consequently, this chapter aims to provide a concise overview of the existing preclinical and clinical evidence that explores the impact of plant-based therapies on the prevention and treatment of neurocognitive disorders.We thoroughly searched different web databases to identify preclinical and clinical studies that investigate the effect of plant-based medicines on cognitive function in animal models, as well as individuals who are healthy, those with mild cognitive decline, or those with Alzheimer's disease. We included studies that examined plant extracts, multi-component herbal preparations, and phytochemicals such as Nigella sativa Linn., Rosmarinus officinalis L., Ginkgo biloba, and Melissa officinalis. The neuroprotective effects of these plants were associated with their anticholinesterase, anti-inflammatory, and antioxidative activities. None of the included studies reported severe adverse reactions.In conclusion, the results of the preclinical and clinical studies indicate the potential benefits of plant-based therapies on neurocognitive disorders. However, more extended and comprehensive clinical studies must confirm these findings thoroughly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Cardiac Primary Prevention Research Center (CPPRC), Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Mohammad@TUMS.Ac.Ir.
- Toxicology and Diseases Group, Pharmaceutical Sciences and Research Center (PSRC), Tehran University of Medical Sciences, Tehran, Iran. Mohammad@TUMS.Ac.Ir.
ORCID-Profile: Ozra Tabatabaei-Malazy, Bayan Azizi, Mohammad Abdollahi
Zitieren
APA
Tabatabaei-Malazy, O., Azizi, B., & Abdollahi, M. (2025). The Use of Natural Products for Preventing Cognitive Decline/Providing Neuroprotection. Handbook of Experimental Pharmacology. https://doi.org/10.1007/164_2024_732
Vancouver
Tabatabaei-Malazy O, Azizi B, Abdollahi M. The Use of Natural Products for Preventing Cognitive Decline/Providing Neuroprotection. Handbook of Experimental Pharmacology. 2025. doi:10.1007/164_2024_732
BibTeX
@article{TabatabaeiMalazy2025,
author = {Tabatabaei-Malazy, Ozra and Azizi, Bayan and Abdollahi, Mohammad},
title = {The Use of Natural Products for Preventing Cognitive Decline/Providing Neuroprotection},
journal = {Handbook of Experimental Pharmacology},
year = {2025},
doi = {10.1007/164_2024_732}
}
EUVIMED